The Treatment Outcome of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: A Single Institution Experience

Abstract

Our results demonstrate that high in-field recurrence rate of SCC of the EAC and middle ear even treated with surgery and high dose RT. To improve the treatment outcome of this radio-resistant tumor, our study suggest that concurrent chemoradiotherapy including cisplatin regimen may have benefit for overcoming SCC of the EAC and middle ear. Futher prospective clinical trial is crucial to estimate the contribution. A retrospective review was conducted of the records of 16 patients with SCC of the EAC and middle ear between July 2003 and March 2011. The characteristics of the patients were summarized in Table 1. The median age of the patients was 62 years (range, 41―76 years). The treatment regimens of the surgery followed by concurrent chemoradiotherapy (CRT) group were intravenous cisplatin and fluorouracil (n = 1), oral tegafur gimeracil oteracil potassium (n = 2). One patients treated with definitive CRT was received oral tegafur gimeracil oteracil potassium and intravenous cisplatin. The median dose of the radiotherapy (RT) was 66 Gy (range, 50―70 Gy) at 2 Gy per fraction. Overall survival and progression-free survival rates were calculated according to the Kaplan-Meier method.